Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK/PD of PB-119 in Healthy Volunteers
NCT03062774Phase 1Completed
- Sponsor
- PegBio
- Start
- Nov 2014
- Primary completion
- Sep 2016
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of visepegenatide in type 2 diabetes mellitus (T2DM) (3 arms), sponsored by PegBio. Primary endpoint: Incidence of Treatment-Emergent Adverse Events at Day 50. Started Nov 2014; status: completed.
02
Drugs
visepegenatide
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT03062774.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03062774.